Latest Nephrology news and features
Latest Urology news and features
Download our free app for iOS or Android
The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease. Key to these efforts is the availability of clinically accessible biomarkers that can help distinguish between a wide variety of bone and mineral disturbances related to kidney failure.
Chitosan gum could offer dialysis patients an inexpensive way to control phosphorus nonsystemically without adding to their daily pill burden.
_42248.jpg?format=jpg&zoom=1&quality=70&anchor=middlecenter&height=100&width=144&mode=crop "A Case for Calcium-Based Binders")
This article is the second in a series on hyperphosphatemia management in CKD patients.
Consuming too much phosphorus increases the risk of left ventricular hypertrophy in women, study finds
Combined with use of a binder, this approach raised serum albumin while maintaining target phosphorus levels.
Factors unrelated to mineral metabolism may contribute to the association between high FGF-23 and death in dialysis patients.
Researchers made the discovery in a study of individuals with normal kidney function.
Proteinuria also is linked to high cholesterol.
Reducing phosphate burden may decrease proteinuria and slow progression of renal disease in patients with chronic kidney disease.
Nearly 11% of hemodialysis (HD) patients who discontinued use of a phosphate binder did so because of side effects.
Oral sodium bicarbonate may ease hyperphosphatemia in peritoneal dialysis (PD) patients with metabolic acidosis.
Dietary phosphorus may have an effect on the progression of autosomal dominant polycystic kidney disease.
Serum phosphorus concentrations are significantly lower in elderly hemodialysis (HD) patients compared with younger patients.
Phosphate level is a stronger predictor for increased mortality among hemodialysis (HD) patients than calcium and parathyroid hormone (PTH) levels.
Lanthanum carbonate acts in synergy with dietary phosphate restriction to decrease levels of fibroblast growth factor 23 (FGF-23) in patients with chronic kidney disease (CKD) and normal phosphate levels.
Hyperparathyroidism develops prior to significant hyperphosphatemia in patients with chronic kidney disease (CKD) but not on dialysis.
New findings presented at Kidney Week 2012 suggest that target serum phosphorus levels in patients on maintenance hemodialysis (MHD) may need to be defined.
High serum levels of (iPTH) and dietary protein intake are associated with an increased risk of hyperphosphatemia in patients on MH.
